Your browser doesn't support javascript.
loading
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
Schreibelt, Gerty; Bol, Kalijn F; Westdorp, Harm; Wimmers, Florian; Aarntzen, Erik H J G; Duiveman-de Boer, Tjitske; van de Rakt, Mandy W M M; Scharenborg, Nicole M; de Boer, Annemiek J; Pots, Jeanette M; Olde Nordkamp, Michel A M; van Oorschot, Tom G M; Tel, Jurjen; Winkels, Gregor; Petry, Katja; Blokx, Willeke A M; van Rossum, Michelle M; Welzen, Marieke E B; Mus, Roel D M; Croockewit, Sandra A J; Koornstra, Rutger H T; Jacobs, Joannes F M; Kelderman, Sander; Blank, Christian U; Gerritsen, Winald R; Punt, Cornelis J A; Figdor, Carl G; de Vries, I Jolanda M.
Afiliación
  • Schreibelt G; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Bol KF; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Westdorp H; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Wimmers F; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Aarntzen EH; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. Radboud Institute for Molecular Life Sciences, Radboud University
  • Duiveman-de Boer T; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • van de Rakt MW; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Scharenborg NM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • de Boer AJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Pots JM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Olde Nordkamp MA; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • van Oorschot TG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Tel J; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Winkels G; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany.
  • Petry K; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany.
  • Blokx WA; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • van Rossum MM; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Welzen ME; Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Mus RD; Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Croockewit SA; Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Koornstra RH; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Jacobs JF; Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Kelderman S; Department of Immunology, Netherlands Cancer Institute NKI-AVL, Amsterdam, the Netherlands.
  • Blank CU; Department of Immunology, Netherlands Cancer Institute NKI-AVL, Amsterdam, the Netherlands.
  • Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Punt CJ; Department of Medical Oncology, Academic Medical Center, Amsterdam, the Netherlands.
  • Figdor CG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • de Vries IJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. jolanda.devries@radboudumc.nl.
Clin Cancer Res ; 22(9): 2155-66, 2016 05 01.
Article en En | MEDLINE | ID: mdl-26712687
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Dendríticas / Monocitos / Vacunas contra el Cáncer / Melanoma / Metástasis de la Neoplasia Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Dendríticas / Monocitos / Vacunas contra el Cáncer / Melanoma / Metástasis de la Neoplasia Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos